Imaging Collaterals in Acute Stroke (iCAS) (iCAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02225730|
Recruitment Status : Recruiting
First Posted : August 26, 2014
Last Update Posted : October 11, 2018
Stroke is caused by a sudden blockage of a blood vessel that delivers blood to the brain. Unblocking the blood vessel with a blood clot removal device restores blood flow and if done quickly may prevent the disability that can be caused by a stroke.
However, not all stroke patients benefit from having their blood vessel unblocked.
The aim of this study is to determine if special brain imaging, called MRI, can be used to identify which stroke patients are most likely to benefit from attempts to unblock their blood vessel with a special blood clot removal device. In particular, we will assess in this trial whether a noncontrast MR imaging sequence, arterial spin labeling (ASL), can demonstrate the presence of collateral blood flow (compared with a gold standard of the angiogram) and whether it is useful to predict who will benefit from treatment.
|Condition or disease|
Intravenous tissue plasminogen activator (IV tPA) is the standard of care treatment for stroke patients when treatment can be initiated within 3 hours after symptom onset. Unfortunately, only a very small fraction of stroke patients is treated with tPA, and benefits from tPA. This is the result of two main limitations of tPA therapy.
First, the proportion of patients that can be treated with iv tPA is small. Because of the narrow three hour time-window during which tPA is effective, only patients who arrive to the hospital early on can be treated with tPA. Most stroke patients, however, arrive at the hospital after the three-hour time-window and are therefore excluded from tPA treatment. Second, stroke patients who receive tPA do not always benefit because the treatment does not restore blood flow in all patients.
Patients with persistent blood vessel occlusions and no improvement in their clinical condition after receiving tPA or those arriving at the hospital outside the 3 hour time window routinely undergo mechanical clot removal to open an occluded blood vessel in the brain.
Mechanical clot removal increases the percentage of stroke patients who achieve recanalization, and as a result may increase the proportion of patients who have good clinical outcomes. However it is unclear for which stroke patients mechanical thrombectomy is most suitable. Although effective at removing blood-clots, it appears that mechanical clot retrieval is not beneficial for all patients. Whereas some patients benefit, others experience no effect, and yet others are likely harmed by mechanical clot retrieval. In order to avoid harm and maximize benefit it is important to know, prior to initiation of the mechanical clot retrieval procedure, if the procedure is likely to result in a clinical improvement. We hypothesize that the response to mechanical clot retrieval can be predicted based on characteristics of an MRI scan obtained just prior to the retrieval procedure. In particular, this study will assess whether a new non-contrast MR imaging method, arterial spin labeling (ASL), which measures cerebral blood flow and can give insight into collateral flow, is effective at predicting who will benefit most from treatment. The investigators hope to learn if these new MRI techniques can help identify which patients are most likely to benefit from mechanical clot removal after receiving tPA.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Imaging Collaterals in Acute Stroke|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||August 2019|
- favorable clinical response [ Time Frame: day 30 ]A "favorable clinical response", defined as an 8-point or more improvement on the NIH score when comparing the baseline score to the 30-day score or NIH score of 0 or a 30-day NIH score of 0-1
- modified Rankin Score [ Time Frame: day 90 ]90 day modified Rankin Score 5-6 and 90 day modified Rankin distribution
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02225730
|Contact: Gregory Zaharchuk, MDemail@example.com|
|Contact: Stephanie Kemp, BSfirstname.lastname@example.org|
|United States, California|
|Eden Medical Center||Terminated|
|Castro Valley, California, United States, 94546|
|Stanford University Medical Center||Recruiting|
|Stanford, California, United States, 94035|
|Principal Investigator: Gregory Zaharchuk, MD|
|Sub-Investigator: Gregory Albers, MD|
|Sub-Investigator: Maarten Lansberg, MD/PhD|
|Sub-Investigator: Anna Finley Caulfield, MD|
|Sub-Investigator: Waimei A Tai, MD|
|Sub-Investigator: Paul George, MD, PhD|
|Sub-Investigator: Chitra Venkat, MBBS, MD|
|Sub-Investigator: Karen Hirsch, MD|
|Sub-Investigator: Nirali Vora, MD|
|Sub-Investigator: Neil Schwartz, MD, PhD|
|Sub-Investigator: Marion Buckwalter, MD, PhD|
|United States, Pennsylvania|
|University of Pittsburgh||Terminated|
|Pittsburgh, Pennsylvania, United States, 15213|
|United States, Washington|
|Seattle, Washington, United States, 98122|
|Principal Investigator:||Gregory Zaharchuk, MD||Stanford University|